西藏药业：截至2025年12月18日前十大流通股东持股占比62.65%

Group 1 - The company announced a share buyback plan to be approved at the fourth temporary meeting of the eighth board of directors on December 18, 2025 [1] - The top ten unrestricted shareholders hold approximately 202 million shares, accounting for 62.65% of the total shares [1] - The largest shareholder is Xizang Kangzhe Enterprise Management Co., Ltd., holding about 104 million shares, which is 32.28% of the total [1] Group 2 - For the first half of 2025, the company's revenue composition shows that pharmaceutical commerce accounts for 97.37%, while pharmaceutical manufacturing accounts for 68.9% [2] - Other business segments contribute only 0.2%, with inter-segment eliminations at -66.47% [2] Group 3 - The company's market capitalization is currently 13.6 billion yuan [3]